In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Direvo Biotech AG

Division of Bayer AG
www.direvo.com

Latest From Direvo Biotech AG

Recent Financings Boost Biotech M&A Returns

A recent influx of venture capital does appear to place start-ups in an optimal position to negotiate better terms and receive a higher payment.
BioPharmaceutical Business Strategies

Mind over matter - partnerships: CNS deals signed over the past five years

Attention deficit hyperactivity disorder (ADHD)

Date

 

Company

 

Partner

 

Deal terms

 

March 2009

 

GlaxoSmithKline

 

Shire

 

co-promotion of Shire's Vyvanse (lisdexamfetamine dimesylate) for the treatment of attention deficit hyperactivity disorder in the US

 

November 2008

 

GlaxoSmithKline

 

Paladin Labs

 

three-year contract giving Paladin exclusive distribution rights for GSK's Dexedrine (dextroamphetamine sulfate) for the treatment of ADHD and in the adjunctive treatment of narcolepsy, in Canada

 

Neurology Mexico

Bayer rules out expensive acquisitions to focus on academia

Bayer is adamant that it will avoid billion-dollar transactions in healthcare this year and has no interest in buying a generics business. Instead it will focus on developing external links with research institutions such as universities, says board chairman Werner Wenning.

Cancer Companies

Reacting to the Crisis: Biotech Venture Capital's Plan B

There are significant dilemmas facing life sciences venture capitalists buffeted by the simultaneous but distinct insults of global financial calamity and trickier-than-ever biotech partnering, regulatory, and reimbursement environments. Venture's best bet at a return is an uptick in decidedly un-venture PIPE deals that take advantage of public biotechs' miserable valuations, but those deals aren't exactly growing on trees. Despite the surfeit of bad news, there may be a bright side.
BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Research, Analytical Equipment & Supplies
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Germany
  • Parent & Subsidiaries
  • Bayer AG
  • Senior Management
  • Thomas von Ruden, PhD, Pres. & CEO
    Andreas F Richter, CFO
    Ulrich Haupts, PhD, VP, Res., Biopharmaceuticals
    Henning Afflerbach, PhD, VP, Bus. Dev., Biopharmaceuticals
  • Contact Info
  • Direvo Biotech AG
    Phone: (49) 221 8887 0
    Nattermannallee 1
    Cologne, D-50829
    Germany
Advertisement
Advertisement
UsernamePublicRestriction

Register